Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis (Q35927136)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

metastatic renal cell carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Alain Ravaud

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Robert Motzer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

S Bracarda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

T E Hutson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

R A Figlin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

E Calvo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

V Grünwald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

D Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

O Anak

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A Panneerselvam

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

B Escudier

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

22 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1475-1480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit

26 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

EAU guidelines on renal cell carcinoma: the 2010 update

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

EORTC-GU group expert opinion on metastatic renal cell cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Sorafenib in advanced clear-cell renal-cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341863

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

2 October 2017

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.89

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.89

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.89

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.89

21 January 2018

Identifiers

DOI

10.1038/BJC.2012.89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

PubMed publication ID

22441644

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441644%20AND%20SRC:MED&resulttype=core&format=json